In its first-quarter 2025 investor letter, TimesSquare Capital U.S. Focus Growth Strategy highlighted stocks such as Cencora, Inc. (NYSE:COR). Cencora, Inc. (NYSE:COR) is a pharmaceutical products ...

Cencora (COR) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues. Cencora (NYSE:COR) announced a notable 15% price ...

The medical device sector saw steady sales growth in the first quarter of 2025, supported by innovation in AI, wearables, and ...

Cencora COR is slated to report second-quarter ... performance in its specialty logistics business, particularly World Courier, due to muted activity in clinical trials and cell and gene therapies.

May 7 (Reuters) - U.S. drug distributor Cencora (COR.N), opens new tab raised its annual profit forecast on Wednesday, driven by robust demand for costly specialty medicines and weight-loss drugs.

Hello, everyone, and thank you for joining the Cencora Fiscal 2025 Second Quarter Results Conference Call. My name is Lucy, and I will be coordinating your call today. [Operator Instructions] I ...

Has Cencora (COR) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out. Cencora is a member of our Medical group, which includes 1002 ...